ORTHOPEDIATRICS CORP
For the period ended Sep 30, 2026. Filed Oct 28, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
ITEM 5. OTHER INFORMATION a. Information required under Form 8-K.
None.
b. Modifications to nomination process.
None.
c. Insider trading arrangements.
During the three months ended September 30, 2026, the Company's Chairman and the following Company Named Executive Officers adopted written trading arrangements intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended:
| Name and title | Date of adoption | Planned Duration Date Range | Aggregate number of shares to be sold |
|---|---|---|---|
| Mark Throdahl, Chairman | August 27, 2026 | November 30, 2026 - November 29, 2027 | 20,772 |
| David Bailey, President & CEO | August 25, 2026 | November 30, 2026 - November 29, 2027 | 20,000 |
| Fred Hite, CFO & COO | September 3, 2026 | December 7, 2026 - December 6, 2027 | 20,000 |
| Greg Odle, President - Scoliosis | September 10, 2026 | December 9, 2026 - December 8, 2027 | 30,000 |
| Joe Hauser, President Trauma & Deformity and OP Specialty Bracing (OPSB) | September 11, 2026 | December 14, 2026 - December 13, 2027 | 5,000 |
| Daniel Gerritzen, EVP - Legal, General Counsel & Secretary | August 25, 2026 | November 30, 2026 - August 29, 2027 | 26,000 |
The arrangements were adopted in accordance with the Company's insider trading policy and applicable securities laws. Moreover, the arrangements are intended to facilitate long-term personal financial planning, diversification and liquidity objectives through pre-established trading parameters.
Other than the arrangements described above, during the three months ended September 30, 2026, no director or executive officer of the Company adopted, modified, orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(c) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.